MYGN
Myriad Genetics, Inc.
Healthcare · Medical - Diagnostics & Research
Undervalued·Quality 80·RSI 50·DCF -533%·Conviction 80
Investment Thesis — Myriad Genetics, Inc.
The market is overly focused on Myriad Genetics' recent revenue declines and high forward P/E, missing the embedded value in its proprietary genetic testing database and the potential for reimbursement tailwinds. Investors are pricing the company as a structurally impaired, commoditized lab, ignoring the optionality from new payer coverage and pipeline expansion.
Catalysts
- Positive reimbursement decision from major payer
- Launch of new high-margin genetic test
- Strategic partnership or acquisition interest
Risk Factors
- Further reimbursement cuts or negative policy changes
- Continued cash burn leading to liquidity crisis
- Loss of key commercial partnerships or data exclusivity
Key Debates
MYGN's 101.78 P/E justified by margin expansion by Q2 2025
Revenue growth exceeds 4.80% by Q3 2025 on new test adoption
MYGN hits $6.00 PT by Q1 2025 from market share gains